INTECH Investment Management
PVLA icon

INTECH Investment Management’s Palvella Therapeutics PVLA Stock Holding History

INTECH Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
2,197
+223
+11% +$27.1K ﹤0.01% 1527
2026
Q1 		$246K Sell
1,974
-1,495
-43% -$156K ﹤0.01% 1656
2025
Q4 		$363K Sell
3,469
-659
-16% -$56.2K ﹤0.01% 1661
2025
Q3 		$259K Buy
+4,128
New +$184K ﹤0.01% 1912

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

INTECH Investment Management's PVLA Position: Q2 2026 in Review

INTECH Investment Management increased its Palvella Therapeutics (PVLA) stake by 11% in Q2 2026, buying an estimated $27.1K and bringing the position to 2,197 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

INTECH Investment Management first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $363K in Q4 2025. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • INTECH Investment Management held 2,197 shares of Palvella Therapeutics worth $336K as of Q2 2026.
  • INTECH Investment Management bought 223 Palvella Therapeutics shares in Q2 2026, an estimated $27.1K.
  • Palvella Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1527 holding.
  • INTECH Investment Management first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • INTECH Investment Management's Palvella Therapeutics position peaked at $363K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.